947144-32-3

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Pyridinone, 4-hydroxy-6-(trifluoromethyl)is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structural features, including the hydroxyl and trifluoromethyl groups, make it a valuable building block in the development of new therapeutic agents.
Used in Chemical Research:
2(1H)-Pyridinone, 4-hydroxy-6-(trifluoromethyl)is used as a research compound in the field of organic chemistry. Its reactivity and structural properties make it an interesting subject for studying reaction mechanisms, synthesis strategies, and the exploration of new chemical transformations.
Used in Material Science:
2(1H)-Pyridinone, 4-hydroxy-6-(trifluoromethyl)is used as a component in the development of new materials with specific properties. The presence of the hydroxyl and trifluoromethyl groups can influence the compound's interactions with other molecules, potentially leading to the creation of materials with unique characteristics, such as improved stability or enhanced reactivity.

InChI:InChI=1/C6H4F3NO2/c7-6(8,9)4-1-3(11)2-5(12)10-4/h1-2H,(H2,10,11,12)

Upstream product

• 947144-28-7 ethyl 2,4-dihydroxy-6-(trifluoromethyl)nicotinate 
• 947144-28-7 4-hydroxy-2-oxo-6-trifluoromethyl-1,2-dihydropyridine-3-carboxylic acid ethyl ester 
• 947144-30-1 3-(2-ethoxycarbonylacetylamino)-4,4,4-trifluorobut-2-enoic acid ethyl ester 

Downstream Products

• 947144-26-5 6-trifluoromethyl-3-nitro-2,4-dihydroxypyridine 
• 947142-81-6 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo[4,5-c]pyridin-2-one 
• 947144-26-5 4-hydroxy-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-53-8 4-chloro-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-38-9 4-benzylamino-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-36-7 benzyl-(2-chloro-3-nitro-6-trifluoromethylpyridin-4-yl)carbamic acid ethyl ester 
• 947144-34-5 (2-amino-3-nitro-6-trifluoromethylpyridin-4-yl)benzylcarbamic acid ethyl ester 

Relevant academic research and scientific papers

Flexible Fragment Growing Boosts Potency of Quorum-Sensing Inhibitors against Pseudomonas aeruginosa Virulence

Hit-to-lead optimization is a critical phase in drug discovery. Herein, we report on the fragment-based discovery and optimization of 2-aminopyridine derivatives as a novel lead-like structure for the treatment of the dangerous opportunistic pathogen Pseudomonas aeruginosa. We pursue an innovative treatment strategy by interfering with the Pseudomonas quinolone signal (PQS) quorum sensing (QS) system leading to an abolishment of bacterial pathogenicity. Our compounds act on the PQS receptor (PqsR), a key transcription factor controlling the expression of various pathogenicity determinants. In this target-driven approach, we made use of biophysical screening via surface plasmon resonance (SPR) followed by isothermal titration calorimetry (ITC)-enabled enthalpic efficiency (EE) evaluation. Hit optimization then involved growth vector identification and exploitation. Astonishingly, the latter was successfully achieved by introducing flexible linkers rather than rigid motifs leading to a boost in activity on the target receptor and anti-virulence potency.

Development of a practical synthesis of Toll-like receptor agonist PF-4171455: 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo [4,5-c] pyridin-2-one

The development and implementation of a scalable process for the manufacture of the Toll-like receptor (TLR7) agonist PF-4171455 (1) is described. Initial routes used to synthesise 1 in milligram quantities were unsuitable for large-scale synthesis to pro

SPRAY DRIED FORMULATION

Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/mL in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt% of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt% of the solid dispersion.

NOVEL PHARMACEUTICALS

The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.